Compare DexCom, Inc. (DXCM) vs Standard Lithium Ltd (SLI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs Standard Lithium Ltd — how do they compare? DexCom, Inc. trades at $90.22 (market cap $33.79B), while Standard Lithium Ltd trades at $2.41 (market cap $604.50M). The key difference: DexCom, Inc. is far larger — about 55.9× Standard Lithium Ltd's market cap, and DexCom, Inc. is trading nearer its 52-week high, Standard Lithium Ltd nearer its low. Which is the better fit depends on your goals.
| DXCM | SLI | |
|---|---|---|
Market Cap | $33.79B | $604.50M |
Sector | Health | Basic Materials |
52-Week High | $89.53 | $5.65 |
52-Week Low | $54.84 | $1.93 |
Enterprise Value | $33.24B | $467.42M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DXCM trades at $90.23, up 2.94% today and near its 52-week high, with a bullish technical signal from moving averages. The company reported strong Q2 2026 earnings, beating EPS estimates with $0.70 versus $0.61 expected, and raised full-year guidance. Revenue growth remains robust at 13% year-over-year, supported by G7 system adoption and international expansion. Profit margins improved, with net income margin reaching 20.12% in 2025. Analyst sentiment is overwhelmingly positive, with 80% buy ratings.
The outlook for DXCM is favorable due to sustained demand for continuous glucose monitors and strategic initiatives like 'Road to 100'. Key risks include competitive pressures, regulatory scrutiny, and valuation multiples above industry averages. The stock's current price is slightly above the consensus target of $88.65, suggesting near-term consolidation may occur before further upside.
SLI trades at $2.43, down 3.95% on the day, with a bullish technical signal from moving averages and a neutral oscillator stance. The company reported negative profitability metrics, including a -16.6% ROE and -$48.40M net income for 2025, but has beaten EPS estimates in two recent quarters. Recent news highlights institutional buying and progress on its South West Arkansas lithium project, supported by a $225M DOE grant.
The outlook hinges on successful project execution and lithium production timeline, with analyst consensus strongly bullish (100% buy ratings). Key risks include persistent negative cash flow from operations and high capital expenditure needs, which could pressure the balance sheet if project delays occur.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About Standard Lithium Ltd
Standard Lithium Ltd. is a company focused on the development of lithium projects in North America, with a primary focus on extracting lithium from brine resources. Their flagship projects aim to utilize proprietary, advanced direct lithium extraction (DLE) technologies to produce high-purity lithium compounds in an environmentally responsible manner. The company seeks to become a key domestic supplier to the growing electric vehicle and battery storage markets.
Read more on SLI →
